Use of Continuous Subcutaneous Insulin Infusion (CSII), otherwise termed insulin pumps, has been shown to improve glycemic outcomes in Type 1 Diabetes (T1D) [1–4], therefore reducing the risk of associated complications and improving quality of life [5, 6]. This evidence concerns the gene INS and type 1 diabetes mellitus.